Skip to main content

Gene Therapy

Making Gene Therapy Faster And Better With Fuse Vectors



Moorfields Eye Hospital in London made international headlines last week. Doctors announced they had saved the sight of four young children suffering from a rare genetic condition that rapidly causes blindness. The toddlers were treated using gene therapy, through which patients are given a harmless virus containing healthy versions of a defective gene in order to remedy the problem.

“Gene therapy sounds like science fiction, but it is beginning to have a huge impact,” says Benjamin Blaha, co-founder of the gene therapy-focused Danish biotechnology start-up Fuse Vectors, which is today announcing a $5.2 million pre-seed fundraising round. “We desperately need to develop more of these treatments as quickly as possible, because they can save lives and transform patient outcomes.”

Fuse hopes to play a significant role in doing exactly that. Blaha and co-founders Jordan Turnbull and Henrik Stage believe that the bottleneck for gene therapy developers today lies in the manufacturing process, rather than in the science itself. “If we want to develop new treatments faster, more safely and more cheaply, we need to solve the manufacturing problem,” Blaha adds. “Traditional methods of manufacturing gene therapies are akin to asking a blacksmith to build a jet plane.”

Fuse is focused on the mechanics of getting treatments into the human body – the “vector” for transmission. Currently, gene therapies make use of human cells – a technique developed for other types of drug delivery – but working with live cells in this way is inefficient and difficult to control. Fuse’s innovation is a technique that enables cell-free production of the viral vectors required; using protein and DNA as building blocks, it constructs tailor-made vectors for delivering the treatment.

“This allows for greater precision, more efficiency and increased scalability,” explains Turnbull. “You get higher drug quality, improving safety and efficacy by eliminating unwanted by-products, increased development speed from research to clinical application, and reduced production costs that make advanced therapies more affordable.”

The potential gains are significant. Fuse believes that its finished product is so tightly controlled that patients will need only a fifth of the dose currently required from gene therapies, which should be far safer. It says it can develop a new viral vector for testing in just four hours – compared to the four weeks it takes to develop a cell in the traditional way. And it thinks costs could be dramatically lower.

All of which is hugely exciting for healthcare professionals and the patients they want to treat. “There are thousands of addressable diseases that we need these therapies for,” adds Blaha. “The opportunity is to transform people’s lives.”

That said, the company is at a relatively early stage – particularly in terms of commercialisation. Fuse is pre-revenue, though it has signed up around a dozen partners, ranging from pharmaceutical companies to academic institutions, which will trial its technology in the coming months. The two founders hope to convert some of those partners into paying customers before the end of the year.

The company is pursuing two business models, with plans both to develop its own gene therapies and to give access to its manufacturing process to other developers. “The key is just to develop these treatments as quickly as possible,” says Turnbull.

New funding for the business should help in this endeavour. Today’s $5.2 million round is led by HCVC, an early-stage venture capital firm with investments in both Europe and North America. “With its unique cell-free viral vector solution, expert founding team and strong business model, Fuse Vectors has the potential to overcome significant challenges in the field,” says HCVC managing partner Alexis Houssou. “We believe in their ability to bring transformative treatments to patients.”

The funding round has also won support from BioInnovation Institute, an international non-profit foundation supported by the Novo Nordisk Foundation, and Denmark’s Export & Investment Fund. At the former, chief business officer Trine Bartholdy, says: “Fuse’s approach has the potential to make gene therapy much more interesting for the industry to develop as well as to increase its accessibility to patients.”

gene therapy, genetic engineering, genome editing, CRISPR, gene modification, genetic disorders, DNA repair, viral vectors, non-viral delivery, somatic gene therapy, germline editing, gene expression, targeted therapy, biotechnology, precision medicine, RNA therapeutics, cell therapy, molecular medicine, hereditary diseases, biomedical research

#GeneTherapy #GeneticEngineering #GenomeEditing #CRISPR #GeneModification #GeneticDisorders #DNARepair #ViralVectors #NonViralDelivery #SomaticGeneTherapy #GermlineEditing #GeneExpression #TargetedTherapy #Biotechnology #PrecisionMedicine #RNATherapeutics #CellTherapy #MolecularMedicine #HereditaryDiseases #BiomedicalResearch

Comments

Post a Comment

Popular posts from this blog

Genetics role in ovarian cancer

The Medical Minute: Genetics play big role in ovarian cancer In 2024, about 19,680 women in the United States will receive a new diagnosis of ovarian cancer and 12,740 women will die from the disease, said Dr. Shaina Bruce , a gynecologic oncologist at Penn State Cancer Institute . The median age of all patients who develop ovarian cancer is 63. Historically, women at increased risk for ovarian cancer are recommended to have their fallopian tubes and ovaries removed when they have completed having children. Taking that step to protect themselves comes at a heavy price ― surgical menopause. But Bruce said medical science is catching up with ovarian cancer. Studies could lead to new methods for preventative care and the surgery needed to lower risk may be easier than it once was. Below, during Gynecologic Cancer Awareness Month, Bruce discusses the disease and why acting to reduce your risk is worth it. What’s the connection between heredity and ovarian cancer? About 25% of all cases of ...
Post a Comment
Read more

Multifactorial Genetic Conditions

Multifactorial Genetic Conditions Multifactorial genetic conditions are disorders caused by the combined effects of multiple genes and environmental factors , rather than a single gene mutation . These conditions do not follow classic Mendelian inheritance patterns and instead result from complex gene–environment interactions . Factors such as lifestyle, nutrition, infections, stress, and exposure to toxins can significantly influence disease onset and severity in genetically susceptible individuals. Common examples include diabetes, cardiovascular diseases , neural tube defects, asthma, and many neuropsychiatric disorders. Understanding multifactorial inheritance is essential for risk prediction, preventive medicine, and personalized healthcare strategies. Multifactorial inheritance, polygenic traits, gene–environment interaction, complex diseases, genetic susceptibility, environmental risk factors, non-Mendelian inheritance, disease predisposition, polygenic risk score, precision ...
Post a Comment
Read more

X chromosome

Gene on the X chromosome may help explain high multiple sclerosis rates in women Brain inflammation may be fueled by a gene on the X chromosome, a new study in mice suggests. And in female mice, who carry two X chromosomes, a diabetes drug called metformin may work to counteract that inflammation. If these findings bear out in later studies, they could help to unravel the long-standing mystery of why women, who have two copies of this inflammation-driving gene, are more prone to certain autoimmune diseases, particularly after menopause. A disparity between the sexes Our bodies are patrolled by immune cells that provide protection against bacteria and viruses, but sometimes, these defenses turn on us. In the autoimmune disorder multiple sclerosis (MS), for instance, the immune system attacks myelin, the fatty insulation surrounding the nerve fibers in the brain and spinal cord. This leads to symptoms such as muscle weakness and difficulty walking, as well issues with memory and thinking...
Post a Comment
Read more